 Psychedelics-focused biotech company Mind Medicine Inc. NASDAQ: MNMD NEO: MMED DE: MMQ announced the publication of its first data on the interaction of a selective serotonin uptake inhibitor, known as escitalopram, with an acute response to psilocybin in humans. The publication is based on a randomized, double-blind, placebo-controlled, crossover pharmacology study in healthy volunteers and was published in Clinical Pharmacology and Therapeutics. 